{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T14:59:29Z","timestamp":1791644369125,"version":"4.3.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100006378","name":"Universitas Indonesia","doi-asserted-by":"crossref","award":["NKB-168\/UN2.RST\/HKP.05.00\/2022"],"award-info":[{"award-number":["NKB-168\/UN2.RST\/HKP.05.00\/2022"]}],"id":[{"id":"10.13039\/501100006378","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Res."],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s44313-025-00096-0","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T13:42:57Z","timestamp":1756734177000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["RUNX1 alterations and survival outcomes in AML: leukocyte dynamics and thrombocytosis insights from an Indonesian cohort"],"prefix":"10.1007","volume":"60","author":[{"given":"Ikhwan","family":"Rinaldi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elly Yanah","family":"Arwanih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Winston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farida Farah","family":"Adibah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuli Maulidiya","family":"Shufiyani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafida Amalia","family":"Salma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"issue":"7","key":"96_CR1","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41568-020-0260-3","volume":"20","author":"M Yamashita","year":"2020","unstructured":"Yamashita M, Dellorusso PV, Olson OC, Passegu\u00e9 E. Dysregulated haematopoietic stem cell behaviour in myeloid leukaemogenesis. Nat Rev Cancer. 2020;20(7):365\u201382.","journal-title":"Nat Rev Cancer"},{"issue":"10147","key":"96_CR2","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","volume":"392","author":"NJ Short","year":"2018","unstructured":"Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet. 2018;392(10147):593\u2013606.","journal-title":"Lancet"},{"issue":"6","key":"96_CR3","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1093\/ajcp\/aqaa107","volume":"154","author":"DA Arber","year":"2020","unstructured":"Arber DA, Erba HP. Diagnosis and treatment of patients with acute myeloid leukemia with myelodysplasia-related changes (AML-MRC). Am J Clin Pathol. 2020;154(6):731\u201341.","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"96_CR4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s43042-024-00563-w","volume":"25","author":"A Debnath","year":"2024","unstructured":"Debnath A, Nath S. Prognosis and treatment in acute myeloid leukemia: a comprehensive review. Egypt J Med Hum Genet. 2024;25(1):91.","journal-title":"Egypt J Med Hum Genet"},{"key":"96_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/cells9102310","author":"JP Bewersdorf","year":"2020","unstructured":"Bewersdorf JP, Zeidan AM. Hyperleukocytosis and leukostasis in acute myeloid leukemia: can a better understanding of the underlying molecular pathophysiology lead to novel treatments? Cells. 2020. https:\/\/doi.org\/10.3390\/cells9102310.","journal-title":"Cells"},{"issue":"12","key":"96_CR6","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136\u201352.","journal-title":"N Engl J Med"},{"issue":"3","key":"96_CR7","doi-asserted-by":"publisher","first-page":"366","DOI":"10.3343\/alm.2015.35.3.366","volume":"35","author":"E You","year":"2015","unstructured":"You E, Cho SY, Yang JJ, Lee HJ, Lee WI, Lee J, et al. A novel case of extreme thrombocytosis in acute myeloid leukemia associated with isochromosome 17q and copy neutral loss of heterozygosity. Ann Lab Med. 2015;35(3):366\u20139.","journal-title":"Ann Lab Med"},{"issue":"2","key":"96_CR8","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000180","volume":"3","author":"BR Schnell","year":"2019","unstructured":"Schnell BR, Seipel K, Bacher U, Jeker B, Mueller BU, Banz Y, et al. Rebound thrombocytosis after induction chemotherapy is a strong biomarker for favorable outcome in AML patients. Hemasphere. 2019;3(2): e180.","journal-title":"Hemasphere"},{"issue":"1","key":"96_CR9","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1093\/ajcp\/aqx046","volume":"148","author":"E You","year":"2017","unstructured":"You E, Cho YU, Jang S, Seo EJ, Lee JH, Lee JH, et al. Frequency and clinicopathologic features of RUNX1 mutations in patients with acute myeloid leukemia not otherwise specified. Am J Clin Pathol. 2017;148(1):64\u201372.","journal-title":"Am J Clin Pathol"},{"key":"96_CR10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3389\/fcell.2017.00111","volume":"5","author":"DC Bellissimo","year":"2017","unstructured":"Bellissimo DC, Speck NA. RUNX1 mutations in inherited and sporadic leukemia. Front Cell Dev Biol. 2017;5:111.","journal-title":"Front Cell Dev Biol"},{"issue":"15","key":"96_CR11","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1182\/blood-2016-10-687830","volume":"129","author":"R Sood","year":"2017","unstructured":"Sood R, Kamikubo Y, Liu P. Role of RUNX1 in hematological malignancies. Blood. 2017;129(15):2070\u201382.","journal-title":"Blood"},{"issue":"1","key":"96_CR12","doi-asserted-by":"publisher","first-page":"99516","DOI":"10.5493\/wjem.v15.i1.99516","volume":"15","author":"HM Abd El-Ghany","year":"2025","unstructured":"Abd El-Ghany HM, El Ashry MS, Abdellateif MS, Rabea A, Sultan N, Abd El Dayem OY. Prevalence of RUNX1 gene alterations in de novo adult acute myeloid leukemia. World J Exp Med. 2025;15(1):99516.","journal-title":"World J Exp Med."},{"issue":"22","key":"96_CR13","doi-asserted-by":"publisher","first-page":"8457","DOI":"10.1002\/cam4.3467","volume":"9","author":"RQ Wang","year":"2020","unstructured":"Wang RQ, Chen CJ, Jing Y, Qin JY, Li Y, Chen GF, et al. Characteristics and prognostic significance of genetic mutations in acute myeloid leukemia based on a targeted next-generation sequencing technique. Cancer Med. 2020;9(22):8457\u201367.","journal-title":"Cancer Med"},{"issue":"12","key":"96_CR14","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345\u201377.","journal-title":"Blood"},{"issue":"2","key":"96_CR15","first-page":"325","volume":"19","author":"M Jalili","year":"2018","unstructured":"Jalili M, Yaghmaie M, Ahmadvand M, Alimoghaddam K, Mousavi SA, Vaezi M, et al. Prognostic value of RUNX1 mutations in AML: A meta-analysis. Asian Pac J Cancer Prev. 2018;19(2):325\u20139.","journal-title":"Asian Pac J Cancer Prev"},{"key":"96_CR16","doi-asserted-by":"publisher","first-page":"7100","DOI":"10.12659\/MSM.910916","volume":"24","author":"F Zhu","year":"2018","unstructured":"Zhu F, Huang R, Li J, Liao X, Huang Y, Lai Y. Identification of key genes and pathways associated with RUNX1 mutations in acute myeloid leukemia using bioinformatics analysis. Med Sci Monit. 2018;24:7100\u20138.","journal-title":"Med Sci Monit"},{"issue":"13","key":"96_CR17","doi-asserted-by":"publisher","first-page":"3797","DOI":"10.1111\/jcmm.17424","volume":"26","author":"M Parsa-Kondelaji","year":"2022","unstructured":"Parsa-Kondelaji M, Ayatollahi H, Rostami M, Sheikhi M, Barzegar F, Afzalaghaee M, et al. Evaluating the frequency, prognosis and survival of RUNX1 and ASXL1 mutations in patients with acute myeloid leukaemia in northeastern Iran. J Cell Mol Med. 2022;26(13):3797\u2013801.","journal-title":"J Cell Mol Med"},{"key":"96_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14215239","author":"T Rungjirajittranon","year":"2022","unstructured":"Rungjirajittranon T, Siriwannangkul T, Kungwankiattichai S, Leelakanok N, Rotchanapanya W, Vittayawacharin P, et al. Clinical outcomes of acute myeloid leukemia patients harboring the RUNX1 mutation: is it sStill an unfavorable prognosis? A cohort study and meta-analysis. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14215239.","journal-title":"Cancers (Basel)"},{"issue":"10","key":"96_CR19","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1182\/blood.2020008478","volume":"137","author":"MPT Ernst","year":"2021","unstructured":"Ernst MPT, Kavelaars FG, L\u00f6wenberg B, Valk PJM, Raaijmakers M. RUNX1 germline variants in RUNX1-mutant AML: how frequent? Blood. 2021;137(10):1428\u201331.","journal-title":"Blood"},{"issue":"2","key":"96_CR20","first-page":"145","volume":"43","author":"A Yokota","year":"2020","unstructured":"Yokota A, Huo L, Lan F, Wu J, Huang G. The clinical, molecular, and mechanistic basis of RUNX1 mutations identified in hematological malignancies. Mol Cells. 2020;43(2):145\u201352.","journal-title":"Mol Cells"},{"issue":"10","key":"96_CR21","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1200\/JCO.2010.30.7926","volume":"29","author":"VI Gaidzik","year":"2011","unstructured":"Gaidzik VI, Bullinger L, Schlenk RF, Zimmermann AS, R\u00f6ck J, Paschka P, et al. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. J Clin Oncol. 2011;29(10):1364\u201372.","journal-title":"J Clin Oncol"},{"issue":"9","key":"96_CR22","doi-asserted-by":"publisher","first-page":"4845","DOI":"10.1016\/j.sjbs.2021.07.012","volume":"28","author":"A Rehman","year":"2021","unstructured":"Rehman A, Akram AM, Chaudhary A, Sheikh N, Hussain Z, Alsanie WF, et al. RUNX1 mutation and elevated FLT3 gene expression cooperates to induce inferior prognosis in cytogenetically normal acute myeloid leukemia patients. Saudi J Biol Sci. 2021;28(9):4845\u201351.","journal-title":"Saudi J Biol Sci"},{"issue":"12","key":"96_CR23","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.3324\/haematol.2012.064667","volume":"97","author":"PA Greif","year":"2012","unstructured":"Greif PA, Konstandin NP, Metzeler KH, Herold T, Pasalic Z, Ksienzyk B, et al. RUNX1 mutations in cytogenetically normal acute myeloid leukemia are associated with a poor prognosis and up-regulation of lymphoid genes. Haematologica. 2012;97(12):1909\u201315.","journal-title":"Haematologica"},{"issue":"9","key":"96_CR24","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1038\/s41379-020-0531-2","volume":"33","author":"AE Quesada","year":"2020","unstructured":"Quesada AE, Montalban-Bravo G, Luthra R, Patel KP, Sasaki K, Bueso-Ramos CE, et al. Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1. Mod Pathol. 2020;33(9):1678\u201389.","journal-title":"Mod Pathol"},{"issue":"12","key":"96_CR25","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/ajh.26724","volume":"97","author":"S Venugopal","year":"2022","unstructured":"Venugopal S, DiNardo CD, Loghavi S, Qiao W, Ravandi F, Konopleva M, et al. Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia. Am J Hematol. 2022;97(12):1560\u20137.","journal-title":"Am J Hematol"},{"issue":"24","key":"96_CR26","doi-asserted-by":"publisher","first-page":"4213","DOI":"10.1002\/cncr.34495","volume":"128","author":"F Pastore","year":"2022","unstructured":"Pastore F, Pastore A, Rothenberg-Thurley M, Metzeler KH, Ksienzyk B, Schneider S, et al. Molecular profiling of patients with cytogenetically normal acute myeloid leukemia and hyperleukocytosis. Cancer. 2022;128(24):4213\u201322.","journal-title":"Cancer"}],"container-title":["Blood Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-025-00096-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44313-025-00096-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-025-00096-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T01:57:20Z","timestamp":1757469440000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44313-025-00096-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["96"],"URL":"https:\/\/doi.org\/10.1007\/s44313-025-00096-0","relation":{},"ISSN":["2287-979X","2288-0011"],"issn-type":[{"value":"2287-979X","type":"print"},{"value":"2288-0011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]},"assertion":[{"value":"9 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This cohort study involving human participants was conducted in accordance with the ethical standards of the Institutional and National Research Committees and the 1964 Helsinki Declaration. Approval was granted with number KET-597\/UN2.F1\/ETIK\/PPM.00.02\/2002 by the Ethics Committee of Faculty of Medicine, Universitas Indonesia. Written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"49"}}